In isolated guinea-pig papillary muscle ([K+]o: 4.7 mmol/l, stimulation rate: 1 Hz) the verapamil derivative NN-bis-(3,4-dimethoxyphenethyl)-N-methylamine)-HCl (YS035; 0.3-100 mumol/l) increased the action potential duration measured at 90% repolarization level (APD90) up to 132% of control and enhanced the force of contraction (Fc) up to 125% of control while resting potential (RP) and the maximum upstroke velocity (Vmax) remained nearly unchanged. At 300 mumol/l YS 035, the membrane became depolarised and action potentials could no longer be elicited. These effects were reversed during wash-out. The increase of ADP90 was largest at 0.05 Hz, and the drug-induced effect continuously declined with an increase in stimulation frequency to 2 Hz. Control ADP90 was correlated to the absolute increase of ADP90 (r = 0.84). In atrial muscle the effect of YS 035 on APD90 was more pronounced than in papillary muscle. The Vmax of slow responses ([K+]o: 27 mmol/l, [Ba2+]o: 0.5 mmol/l) was not affected by concentrations as high as 30 mumol/l YS 035, whereas APD90 was enhanced. An increase in the stimulation rate (0.05 to 0.33 Hz) induced only a small decrease of Vmax at 100 mumol/l YS 035. According to this electrophysiological characterisation YS 035 shows Class III antiarrhythmic properties.